Following last week’s announcement of preliminary efficacy data for SRA737, a cancer drug it helped to develop, the company provided the market with an update on other developments within its active pre-clinical portfolio.
Sareum's SDC-1801 and SDC-1802 drug candidates, which are respectively being developed to treat autoimmune diseases and cancers are progressing through pre-clinical development and should undergo first in-human clinical trials in 2020.
Both Sareum programmes have progressed well since being chosen in September 2018 for further development.
Data items arising from some of the development work are being prepared for submission to a peer-reviewed publication and a conference presentation, Sareum said.
Sareum's recent activities have focused on toxicology studies designed to gain insight into the maximum-tolerated doses of SDC-1801 and SDC-1802 in rodents.
SDC-1801, the autoimmune diseases candidate, is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; a maximum tolerated dose has yet to be reached.
In addition, the company has been exploring reliable manufacturing routes to produce each candidate for preclinical and clinical studies; such a route has been developed for SDC-1801 and activities continue to confirm a route of synthesis for SDC-1802.
Sareum Holdings PLC.— Richard Williams (@Fadec92) June 9, 2019
SRA737 + LGD (Low Dose Gem) + PD-L1 Immunotherapy Checkpoint Blockage.
ICB = Keytruda Merck.
100% Regression of Tumors After 21 days in SCLC Small Cell Lung Cancer.
Accounts for 15% Lung Cancers cases in the US.
Design of Human Trial in Process.$SAR.L pic.twitter.com/yRPvuwulP2
"We believe there is a clear opportunity to generate significant value for our shareholders over the next 12 months, given recent progress with both our clinical and preclinical programmes,” said Dr Tim Mitchell, the chief executive officer of Sareum.
Shares in Sareum were up 4.8% in early deals.